DIA’s Annual Canadian Meeting: Thinking Globally, Acting Locally for The Well-Being of the Patient

With a focus on transparency and openness for increased health benefits and mitigated health risks, regulatory agencies in consultation with drug manufacturers and in collaboration with other key stakeholders and partners are strengthening the approach taken to communicate with patients and consumers. This session will focus on initiatives taken by government agencies and drug manufacturers to make available drug product information in plain language. The concept of available, clear, comprehensive and useful information related to authorized medicines is guiding the strategies for improved guidance, new regulations and increased communication to patients/consumers.